Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBC conditioning regimen for haplo-identical allo-HSCT in refractory/relapsed AML
ChiCTR2300072012Phase 4Recruiting
- Sponsor
- Suzhou Hongci Hematology Hospital
- Start
- May 2023
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of thiotepa, cyclophosphamide and busulfan in acute myeloid leukemia (AML), sponsored by Suzhou Hongci Hematology Hospital. Primary endpoint: Relapse-free survival. Started May 2023; status: recruiting.
02
Drugs
thiotepacyclophosphamidebusulfan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300072012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072012.